| P50 | author | Shabnum Patel | Q87592399 |
| | Catherine M Bollard | Q91774704 |
| P2093 | author name string | Douglas F Nixon | |
| | R Brad Jones | |
| P2860 | cites work | Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Q22242245 |
| | RNA-guided human genome engineering via Cas9 | Q24598394 |
| | Genetic engineering of T cells for adoptive immunotherapy | Q24642718 |
| | FokI dimerization is required for DNA cleavage | Q24657843 |
| | Adoptive T cell therapy for cancer in the clinic | Q24680405 |
| | Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis | Q26830838 |
| | CD4 T-cell immunotherapy for chronic viral infections and cancer | Q27022957 |
| | Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes | Q27324527 |
| | Engineering T Cells to Functionally Cure HIV-1 Infection | Q28086801 |
| | Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 |
| | Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells | Q28237048 |
| | Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection | Q28245039 |
| | Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins | Q28267567 |
| | Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 |
| | CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 | Q28307312 |
| | Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells | Q28754733 |
| | Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 |
| | Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases | Q29615069 |
| | DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 |
| | High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 |
| | PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 |
| | T cell exhaustion | Q29620463 |
| | Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection | Q33817504 |
| | Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases | Q33886716 |
| | HIV preferentially infects HIV-specific CD4+ T cells | Q33958893 |
| | Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection | Q34093225 |
| | Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. | Q34468117 |
| | Clinical application of genetically modified T cells in cancer therapy | Q34511646 |
| | Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction | Q34570127 |
| | Enhancing SIV-specific immunity in vivo by PD-1 blockade | Q34601856 |
| | Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers | Q34625953 |
| | Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 |
| | Chemokine receptor 5 knockout strategies | Q34734219 |
| | HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo | Q35029956 |
| | Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells | Q35202343 |
| | HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure | Q35447267 |
| | Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 |
| | Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 | Q35556061 |
| | Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy | Q35653249 |
| | Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir | Q35812943 |
| | Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment | Q35876209 |
| | Length-encoded multiplex binding site determination: application to zinc finger proteins | Q35896081 |
| | Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates | Q35928777 |
| | Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness | Q36080586 |
| | Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses | Q36086732 |
| | Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. | Q36181852 |
| | Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 |
| | The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers | Q36208223 |
| | Change in coreceptor use correlates with disease progression in HIV-1--infected individuals | Q36376800 |
| | Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 |
| | How do CARs work?: Early insights from recent clinical studies targeting CD19. | Q36476104 |
| | Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory act | Q36484055 |
| | Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis | Q36545348 |
| | Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation | Q36578672 |
| | Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection | Q36979967 |
| | Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 |
| | Exploiting the curative potential of adoptive T-cell therapy for cancer | Q37576033 |
| | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care | Q37592177 |
| | Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions | Q37644041 |
| | CD19-CAR trials | Q37692134 |
| | Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Q37723469 |
| | HIV-specific CD4 T cells and immune control of viral replication | Q37866624 |
| | From crucial to negligible: functional CD8⁺ T-cell responses and their dependence on CD4⁺ T-cell help | Q38005963 |
| | HIV infection and depression | Q38189503 |
| | HIV-1 adaptation to HLA: a window into virus-host immune interactions | Q38329384 |
| | High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges | Q38498286 |
| | Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. | Q38889625 |
| | Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells | Q39113639 |
| | CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus | Q39119223 |
| | An unbiased genome-wide analysis of zinc-finger nuclease specificity | Q39493921 |
| | T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. | Q40501551 |
| | Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor | Q41410840 |
| | The functional aspects of bacterial CRISPR-cas systems and interactions between phages and its bacterial hosts--a review | Q41678465 |
| | CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice | Q41721624 |
| | Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects | Q41750120 |
| | CD4 T-cell regeneration in HIV-1 elite controllers | Q41996620 |
| | Safety and stability of retrovirally transduced chimeric antigen receptor T cells | Q44057238 |
| | A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy | Q44165805 |
| | Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. | Q45760355 |
| | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals | Q45862722 |
| | In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 |
| | Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. | Q49086716 |
| | A multi-step pace towards a cure for HIV: kick, kill, and contain. | Q51866015 |
| | HIV: Shock and kill. | Q55056512 |
| | Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression | Q71803154 |
| | Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2 | Q82971212 |
| | [HIV-1 eradication with the "shock and kill" strategy] | Q84122710 |
| | Multiple Roles of CD4 and CD8 in T Cell Activation | Q84774251 |
| P433 | issue | 8 | |
| P304 | page(s) | 931-942 | |
| P577 | publication date | 2016-06-02 | |
| P1433 | published in | Cytotherapy | Q5201399 |
| P1476 | title | T-cell therapies for HIV: Preclinical successes and current clinical strategies | |
| P478 | volume | 18 | |